A detailed history of Benjamin Edwards Inc transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Benjamin Edwards Inc holds 133 shares of VRTX stock, worth $66,825. This represents 0.01% of its overall portfolio holdings.

Number of Shares
133
Previous 114 16.67%
Holding current value
$66,825
Previous $48,000 29.17%
% of portfolio
0.01%
Previous 0.01%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$392.81 - $485.53 $7,463 - $9,225
19 Added 16.67%
133 $62,000
Q1 2024

Apr 29, 2024

BUY
$407.69 - $446.08 $46,476 - $50,853
114 New
114 $48,000
Q2 2022

Aug 12, 2022

SELL
$234.96 - $292.55 $3,994 - $4,973
-17 Closed
0 $0
Q1 2022

May 04, 2022

BUY
$221.42 - $260.97 $1,992 - $2,348
9 Added 112.5%
17 $4,000
Q4 2021

Feb 07, 2022

BUY
$177.01 - $223.45 $531 - $670
3 Added 60.0%
8 $2,000
Q3 2021

Nov 02, 2021

BUY
$181.39 - $202.99 $906 - $1,014
5 New
5 $1,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Benjamin Edwards Inc Portfolio

Follow Benjamin Edwards Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Benjamin Edwards Inc, based on Form 13F filings with the SEC.

News

Stay updated on Benjamin Edwards Inc with notifications on news.